Journal of Stroke & Cerebrovascular Diseases
Volume 19, Issue 2 , Pages 116-120 , March 2010

Does Mild Deficit for Patients with Stroke Justify the Use of Intravenous Tissue Plasminogen Activator?

  • Ameer E. Hassan, DO

      Affiliations

    • University of Medicine and Dentistry of New Jersey, Newark, New Jersey
    • ,
  • Haralabos Zacharatos, DO

      Affiliations

    • University of Minnesota, Minneapolis, Minnesota
    • ,
  • Bahareh Hassanzadeh, MD

      Affiliations

    • University of Medicine and Dentistry of New Jersey, Newark, New Jersey
    • ,
  • Ahmed El-Gengaihy, MD

      Affiliations

    • University of Medicine and Dentistry of New Jersey, Newark, New Jersey
    • ,
  • Ammar AlKawi, MD

      Affiliations

    • University of Medicine and Dentistry of New Jersey, Newark, New Jersey
    • ,
  • Akram Shhadeh, MD

      Affiliations

    • University of Medicine and Dentistry of New Jersey, Newark, New Jersey
    • ,
  • Jawad F. Kirmani, MD

      Affiliations

    • University of Medicine and Dentistry of New Jersey, Newark, New Jersey
    • Corresponding Author InformationAddress correspondence to Jawad F. Kirmani, MD, Assistant Professor, Director of Stroke & Cerebrovascular Program, Department of Neurology and Neurosciences, UMDNJ-New Jersey Medical School, 90 Bergen Street, DOC 8100, Newark, NJ 07103.

Received 30 December 2008 ,Revised 24 March 2009 ,Accepted 26 March 2009.

References 

  1. Centers for Disease Control and Prevention. Prevalence of disabilities and associated health conditions among adults–United States, 1999. MMWR Morb Mortal Wkly Rep. 2001;50:120–125
  2. American Heart Association. Heart disease and stroke statistics–2005 update. Dallas (TX): American Heart Association; 2005;
  3. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: Pooled analysis of atlantis, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–774
  4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587
  5. Kimura K, Iguchi Y, Yamashita S, et al. Atrial fibrillation as an independent predictor for no early recanalization after IV-t-PA in acute ischemic stroke. J Neurol Sci. 2008;267:57–61
  6. Jain SV, Morton LD. Ischemic stroke and excellent recovery after administration of intravenous tissue plasminogen activator. Pediatr Neurol. 2008;38:126–129
  7. Litwin T, Członkowska A, Kobayashi A, et al. Thrombolysis in acute ischemic stroke within 3 hours of symptom onset: A report of the first 100 cases. NeurolI Neurochir Pol. 2008;42:1–5
  8. Kwiatkowski TG, Libman RB, Frankel M, et al. NINDS rt-PA Stroke Study Group Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med. 1999;340:1781–1787
  9. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes. The National Institute of Neurological Disorders and Stroke rt-PA stroke study experience. Ann Emerg Med. 2005;46:243–252
  10. Demchuk AM, Tanne D, Hill MD, et al. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001;57:474–480
  11. Molina CA, Montaner J, Abilleira S, et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: A case-control study. Stroke. 2001;32:2821–2827
  12. Broderick JP, Lu M, Kothari R, et al. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke. 2000;31:2335–2341
  13. Baumann CR, Baumgartner RW, Gandjour J, et al. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke. 2006;37:1332–1333
  14. Smith EE, Abdullah AR, Petkovska I, et al. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke. 2005;36:2497–2499
  15. Kapral MK, Fang J, Hill MD, et al. Sex differences in stroke care and outcomes: Results from the registry of the Canadian stroke network. Stroke. 2005;36:809–814
  16. Kent DM, Price LL, Ringleb P, et al. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: A pooled analysis of randomized clinical trials. Stroke. 2005;36:62–65
  17. Elkind MS, Prabhakaran S, Pittman J, et al. Sex as a predictor of outcomes in patients treated with thrombolysis for acute stroke. Neurology. 2007;68:842–848
  18. Brott T, Adams HP, Olinger CP, et al. Measurements of acute cerebral infarction: A clinical examination scale. Stroke. 1989;20:864–870
  19. Van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604–607
  20. Barber PA, Zhang J, Demchuk AM, et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015–1020
  21. Vaishnav AG, Pettigrew LC, Ryan S. Telephonic guidance of systemic thrombolysis in acute ischemic stroke: Safety outcome in rural hospitals. Clin Neurol Neurosurg. 2008;110:451–454
  22. Martínez-Pérez M, Cánovas-Vergé D, Carvajal-Díaz A. Fibrinolytic treatment with tissue plasminogen activator: Outcomes in clinical practice with a multidisciplinary model of intervention. Rev Neurol. 2007;45:129–133(abstr)
  23. Uyttenboogaart M, Koch MW, Koopman K, et al. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol. 2008;65:607–611
  24. Batmanian JJ, Lam M, Matthews C, et al. A protocol-driven model for the rapid initiation of stroke thrombolysis in the emergency department. Med J Aust. 2007;187:567–570
  25. Yoneda Y, Yamamoto S, Hara Y, et al. Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit. Clin Neurol Neurosurg. 2007;109:567–570
  26. Barroso B, Larrieu JM, Morisset C, et al. Feasibility of stroke thrombolysis at Pau Hospital, France. [in French] Presse Med. 2007;36:859–866(abstr)
  27. Schwammenthal Y, Drescher MJ, Merzeliak O, et al. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: Initial Israeli experience. Isr Med Assoc J. 2004;6:70–74
  28. Heushmann PU, Kolominsky-Rabas PL, Roether J, et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA. 2004;292:1831–1938
  29. Sylaja PN, Cote R, Buchan AM, et al. Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators Thrombolysis in patients older than 80 years with acute ischemic stroke: Canadian alteplase for stroke effectiveness study. J Neurol Neurosurg Psychiatry. 2006;77:826–829
  30. Simon JE, Sandler DL, Warwick Pexman JH, et al. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischemic stroke? The Calgary experience. Age Ageing. 2004;33:143–149
  31. Engelter ST, Reichhart M, Sekoranja L, et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology. 2005;65:1795–1798
  32. Muir KW, Weir CJ, Murray GD. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke. 1996;27:1817–1820
  33. DeGraba LB, Hallenbeck JM, Pettigrew KD, et al. Progression in acute stroke: Value of the initial NIH stroke scale score on patient stratification in future trials. Stroke. 1999;20:1208–1212
  34. Adams HP, Davis PH, Leira EC, et al. Baseline NIH stroke scale score strongly predicts outcome after stroke: A report of the trial of org 10172 in acute stroke treatment (TOAST). Neurology. 1999;25:126–131

PII: S1052-3057(09)00068-8

doi: 10.1016/j.jstrokecerebrovasdis.2009.03.019

Journal of Stroke & Cerebrovascular Diseases
Volume 19, Issue 2 , Pages 116-120 , March 2010

Article Tools

* Image Usage & Resolution